Downregulation of IRF4 expression by shRNA and lenalidomide selectively killed non-GCB-DLBCL and showed a synergistic effect in combination with ibrutinib [72,73], which indicates that IRF4 is a key regulator in ABC-DLBCL survival. This evidence concerns the gene IRF4 and diffuse large B-cell lymphoma.